AtriCure (ATRC)
(Delayed Data from NSDQ)
$23.17 USD
+0.56 (2.48%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $23.16 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Price, Consensus and EPS Surprise
ATRC 23.17 +0.56(2.48%)
Will ATRC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ATRC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATRC
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
ATRC: What are Zacks experts saying now?
Zacks Private Portfolio Services
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
Seeking Clues to AtriCure (ATRC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should Know
Other News for ATRC
AtriCure upgraded at Oppenheimer on valuation
Oppenheimer more bullish on AtriCure, upgrades to Outperform
Oppenheimer gets more bullish on AtriCure, upgrades shares
First Week of June 21st Options Trading For AtriCure (ATRC)
Oppenheimer medical devices analysts hold analyst/industry conference call